Trial design-OV25

ENGOT-OV25/PAOLA-1

Clinical Trial Study: OV25

Phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.

Study design